{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T17:13:23Z","timestamp":1773076403441,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12185-025-04029-6","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T07:40:21Z","timestamp":1751528421000},"page":"671-678","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical features and outcomes of primary ocular adnexal follicular lymphoma: a retrospective analysis"],"prefix":"10.1007","volume":"122","author":[{"given":"Shohei","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Makita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Miyagi-Maeshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhi","family":"Makino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Iwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suguru","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Igaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigenobu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"4029_CR1","doi-asserted-by":"crossref","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36:1720\u201348.","DOI":"10.1038\/s41375-022-01620-2"},{"key":"4029_CR2","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140:1229\u201353.","journal-title":"Blood"},{"key":"4029_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/01.pas.0000213350.49767.46","volume":"31","author":"JA Ferry","year":"2007","unstructured":"Ferry JA, Fung CY, Zukerberg L, Lucarelli MJ, Hasserjian RP, Preffer FI, et al. Lymphoma of the ocular adnexa: A study of 353 cases. Am J Surg Pathol. 2007;31:170\u201384.","journal-title":"Am J Surg Pathol"},{"key":"4029_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/hon.741","volume":"22","author":"J Meunier","year":"2004","unstructured":"Meunier J, Lumbroso-Le Rouic L, Vincent-Salomon A, Dendale R, Asselain B, Arnaud P, et al. Ophthalmologic and intraocular non-Hodgkin\u2019s lymphoma: a large single centre study of initial characteristics, natural history, and prognostic factors. Hematol Oncol. 2004;22:143\u201358.","journal-title":"Hematol Oncol"},{"key":"4029_CR5","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1167\/iovs.08-1768","volume":"49","author":"LD Sjo","year":"2008","unstructured":"Sjo LD, Ralfkiaer E, Prause JU, Petersen JH, Madsen J, Pedersen NT, et al. Increasing incidence of ophthalmic lymphoma in Denmark from 1980 to 2005. Invest Ophthalmol Vis Sci. 2008;49:3283\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4029_CR6","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258\u201365.","journal-title":"Blood"},{"key":"4029_CR7","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555\u201362.","journal-title":"J Clin Oncol"},{"key":"4029_CR8","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","volume":"14","author":"MP Mac Manus","year":"1996","unstructured":"Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996;14:1282\u201390.","journal-title":"J Clin Oncol"},{"key":"4029_CR9","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0360-3016(01)01747-3","volume":"51","author":"RB Wilder","year":"2001","unstructured":"Wilder RB, Jones D, Tucker SL, Fuller LM, Ha CS, McLaughlin P, et al. Long-term results with radiotherapy for Stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys. 2001;51:1219\u201327.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4029_CR10","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1182\/blood.2019004588","volume":"136","author":"AC Lo","year":"2020","unstructured":"Lo AC, Campbell BA, Pickles T, Aquino-Parsons C, Sehn LH, Connors JM, et al. Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study. Blood. 2020;136:1006\u201310.","journal-title":"Blood"},{"key":"4029_CR11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/blood-2018-04-843540","volume":"133","author":"JL Brady","year":"2019","unstructured":"Brady JL, Binkley MS, Hajj C, Chelius M, Chau K, Balogh A, et al. Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood. 2019;133:237\u201345.","journal-title":"Blood"},{"key":"4029_CR12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/PAS.0b013e31818e6489","volume":"33","author":"OK Weinberg","year":"2009","unstructured":"Weinberg OK, Ma L, Seo K, Beck AH, Pai RK, Morales A, et al. Low stage follicular lymphoma: biologic and clinical characterization according to nodal or extranodal primary origin. Am J Surg Pathol. 2009;33:591\u20138.","journal-title":"Am J Surg Pathol"},{"key":"4029_CR13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/aos.12525","volume":"93","author":"PK Rasmussen","year":"2015","unstructured":"Rasmussen PK, Ralfkiaer E, Prause JU, Sjo LD, Specht L, Rossing HH, et al. Follicular lymphoma of the ocular adnexal region: a nation-based study. Acta Ophthalmol. 2015;93:184\u201391.","journal-title":"Acta Ophthalmol"},{"key":"4029_CR14","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jamaophthalmol.2014.376","volume":"132","author":"PK Rasmussen","year":"2014","unstructured":"Rasmussen PK, Coupland SE, Finger PT, Graue GF, Grossniklaus HE, Honavar SG, et al. Ocular adnexal follicular lymphoma: a multicenter international study. JAMA Ophthalmol. 2014;132:851\u20138.","journal-title":"JAMA Ophthalmol"},{"key":"4029_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","volume":"100","author":"L Lowry","year":"2011","unstructured":"Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100:86\u201392.","journal-title":"Radiother Oncol"},{"key":"4029_CR16","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S1470-2045(20)30686-0","volume":"22","author":"P Hoskin","year":"2021","unstructured":"Hoskin P, Popova B, Schofield O, Brammer C, Robinson M, Brunt AM, et al. 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2021;22:332\u201340.","journal-title":"Lancet Oncol"},{"key":"4029_CR17","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamaoncol.2024.2112","volume":"10","author":"CC Pinnix","year":"2024","unstructured":"Pinnix CC, Dabaja BS, Gunther JR, Fang PQ, Wu SY, Nastoupil LJ, et al. Response-adapted ultralow-dose radiation therapy for orbital indolent B-cell lymphoma: a phase 2 nonrandomized controlled trial. JAMA Oncol. 2024;10:1195\u2013203.","journal-title":"JAMA Oncol"},{"key":"4029_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/annonc\/mdj025","volume":"17","author":"K Tanimoto","year":"2006","unstructured":"Tanimoto K, Kaneko A, Suzuki S, Sekiguchi N, Maruyama D, Kim SW, et al. Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol. 2006;17:135\u201340.","journal-title":"Ann Oncol"},{"key":"4029_CR19","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1182\/blood.V95.12.3922","volume":"95","author":"L Cerroni","year":"2000","unstructured":"Cerroni L, Arzberger E, Putz B, Hofler G, Metze D, Sander CA, et al. Primary cutaneous follicle center cell lymphoma with follicular growth pattern. Blood. 2000;95:3922\u20138.","journal-title":"Blood"},{"key":"4029_CR20","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1097\/PAS.0b013e31802ee4ab","volume":"31","author":"CM Bacon","year":"2007","unstructured":"Bacon CM, Ye H, Diss TC, McNamara C, Kueck B, Hasserjian RP, et al. Primary follicular lymphoma of the testis and epididymis in adults. Am J Surg Pathol. 2007;31:1050\u20138.","journal-title":"Am J Surg Pathol"},{"key":"4029_CR21","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1200\/JCO.2010.32.9193","volume":"29","author":"AI Schmatz","year":"2011","unstructured":"Schmatz AI, Streubel B, Kretschmer-Chott E, Puspok A, Jager U, Mannhalter C, et al. Primary follicular lymphoma of the duodenum is a distinct mucosal\/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. J Clin Oncol. 2011;29:1445\u201351.","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04029-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04029-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04029-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T20:37:20Z","timestamp":1761770240000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04029-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["4029"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04029-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"22 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SM has received honoraria from AstraZeneca, AbbVie, Bristol Myers Squibb, Chugai, Genmab, Gilead, Nippon Shinyaku, Novartis, and Takeda. SF has received honoraria from Janssen, Ono Pharmaceutical, Genmab, AbbVie, Takeda, Nippon Shinyaku, Chugai, AstraZeneca, Otsuka, and Amgen and research funding from Chugai, Loxo Oncology, AbbVie, and Mitsubishi Tanabe Pharma. SF has also served on advisory boards for Genmab. WM has received honoraria from Chugai and research funding from Ono Pharmaceutical, Chugai, Nippon Shinyaku, and Genmab. HI has received research funding from Elekta K.K. SS has received honoraria from Ono Pharmaceutical. KI has received honoraria\/fees from MSD, AstraZeneca, AbbVie, Bristol Myers Squibb, Novartis, Yakult, Kyowa Kirin, Chugai, BeiGene, Genmab, Otsuka, Ono Pharmaceutical, Mitsubishi Tanabe Pharma, Eisai, SymBio, Takeda, Zenyaku, Carna Biosciences, Nippon Shinyaku, Pfizer, Janssen, Daiichi Sankyo, Gilead, Nippon Kayaku, Lilly, Astellas, and Meiji Seika Pharma. KI has also received research funding from MSD, AstraZeneca, AbbVie, Incyte, Bristol Myers Squibb, Novartis, Bayer, Pfizer, Janssen, Yakult, Kyowa Kirin, Daiichi Sankyo, Chugai, BeiGene, Genmab, Loxo Oncology, Otsuka, Regeneron, and Gilead. The other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}